Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion
- PMID: 25621684
- PMCID: PMC4602643
- DOI: 10.1097/MD.0000000000000396
Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion
Erratum in
-
Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion: erratum.Medicine (Baltimore). 2015 Feb;94(6):1. doi: 10.1097/01.md.0000461922.06957.86. Medicine (Baltimore). 2015. PMID: 25803168 Free PMC article.
Abstract
This systematic review examined whether the available evidence justifies using hepatic resection (HR) during later stages of hepatocellular carcinoma (HCC), which contravenes treatment guidelines but is current practice at many medical centers.Official guidelines and retrospective studies recommend different roles for HR for patients with large/multinodular HCC or with HCC involving macrovascular invasion (MVI).Several databases were systematically searched for studies examining the safety and efficacy of HR for treating HCC involving a single large tumor (>5 cm) or multiple tumors, or for treating HCC involving MVI.We identified 50 studies involving 14, 808 patients that investigated the use of HR to treat large/multinodular HCC, and 24 studies with 4389 patients that investigated HR to treat HCC with MVI. Median in-hospital mortality for patients with either type of HCC was significantly lower in Asian studies (2.7%) than in non-Asian studies (7.3%, P < 0.001). Median overall survival (OS) was significantly higher for all Asian patients with large/multinodular HCC than for all non-Asian patients at both 1 year (81% vs 65%, P < 0.001) and 5 years (42% vs 32%, P < 0.001). Similar results were obtained for median disease-free survival at 1 year (61% vs 50%, P < 0.001) and 5 years (26% vs 24%, P < 0.001). However, median OS was similar for Asian and non-Asian patients with HCC involving MVI at 1 year (50% vs 52%, P = 0.45) and 5 years (18% vs 14%, P = 0.94). There was an upward trend in 5-year OS in patients with either type of HCC.HR is reasonably safe and effective at treating large/multinodular HCC and HCC with MVI. The available evidence argues for expanding the indications for HR in official treatment guidelines.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures




Similar articles
-
Systematic Review of Single Large and/or Multinodular Hepatocellular Carcinoma: Surgical Resection Improves Survival.Asian Pac J Cancer Prev. 2015;16(13):5541-7. doi: 10.7314/apjcp.2015.16.13.5541. Asian Pac J Cancer Prev. 2015. PMID: 26225708
-
Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial.JAMA Oncol. 2024 Aug 1;10(8):1047-1054. doi: 10.1001/jamaoncol.2024.1831. JAMA Oncol. 2024. PMID: 38900435 Free PMC article. Clinical Trial.
-
The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma.J Cancer Res Clin Oncol. 2017 Jan;143(1):17-27. doi: 10.1007/s00432-016-2256-7. Epub 2016 Sep 10. J Cancer Res Clin Oncol. 2017. PMID: 27614453 Free PMC article.
-
Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma.Cochrane Database Syst Rev. 2015 Jan 26;1(1):CD006745. doi: 10.1002/14651858.CD006745.pub3. Cochrane Database Syst Rev. 2015. PMID: 25620061 Free PMC article.
-
[Comparison of the efficacy of anatomical resection versus hepatic parenchymal preservation preference in patients with solitary small hepatocellular carcinoma and cirrhosis: a multicenter retrospective study].Zhonghua Gan Zang Bing Za Zhi. 2025 Apr 20;33(4):348-358. doi: 10.3760/cma.j.cn501113-20250315-00097. Zhonghua Gan Zang Bing Za Zhi. 2025. PMID: 40419370 Chinese.
Cited by
-
Intermediate-stage HCC--upfront resection can be feasible.Nat Rev Clin Oncol. 2015 May;12(5). doi: 10.1038/nrclinonc.2014.122-c3. Epub 2015 Apr 7. Nat Rev Clin Oncol. 2015. PMID: 25850549 No abstract available.
-
Developing and Validating an Autophagy Gene-Set-Based Prognostic Signature in Hepatocellular Carcinoma Patients.Int J Gen Med. 2022 Nov 28;15:8399-8415. doi: 10.2147/IJGM.S388592. eCollection 2022. Int J Gen Med. 2022. PMID: 36465273 Free PMC article.
-
Long-term outcome of novel combined surgical-injection treatment (COSIT) for large hepatocellular carcinoma: Stage 2A IDEAL prospective case series.Ann Med Surg (Lond). 2021 Nov 24;72:103098. doi: 10.1016/j.amsu.2021.103098. eCollection 2021 Dec. Ann Med Surg (Lond). 2021. PMID: 34888043 Free PMC article.
-
Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: a prospective study.Eur Radiol. 2024 Feb;34(2):1258-1267. doi: 10.1007/s00330-023-10097-1. Epub 2023 Aug 15. Eur Radiol. 2024. PMID: 37581654 Clinical Trial.
-
Combination of 5-fluorouracil and 2-morphilino-8-phenyl-4H-chromen-4-one may inhibit liver cancer stem cell activity.Tumour Biol. 2016 Aug;37(8):10943-58. doi: 10.1007/s13277-016-4915-3. Epub 2016 Feb 17. Tumour Biol. 2016. PMID: 26886287
References
-
- Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69–90. - PubMed
-
- Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362:1907–1917. - PubMed
-
- European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908–943. - PubMed
-
- Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693–699. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical